With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Managing complement 3 glomerulopathy involves several treatment options aimed at slowing disease progression and protecting kidney function. These may include blood pressure control, steroids, ...

There are two types of complement 3 glomerulopathy: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). DDD often begins earlier in life and may progress more quickly. Both are linked to an ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

CTx001, a gene therapy for geographic atrophy, received FDA Fast Track Designation, expediting its development and review process. The Opti-GAIN phase 1/2 trial will assess CTx001's safety, ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...

Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class complement inhibitor for ...

Share on Pinterest A study offers new clues on why long COVID persists in some individuals. krisanapong detraphiphat/Getty Images Despite the debilitating nature of long COVID, there is an absence of ...

Targeting the alternative complement pathway is an attractive therapeutic strategy given its role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is an oral, proximal ...